First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases

Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months. Pediatric patients are exceedingly rare with an unclear clinical course. Currently, no...

Full description

Bibliographic Details
Published in:Journal of Hematology & Oncology
Main Authors: Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal, Anthony Stein
Format: Article
Language:English
Published: BMC 2018-05-01
Subjects:
Pediatric
BPDCN
SL-401
Targeted therapy
Online Access:http://link.springer.com/article/10.1186/s13045-018-0604-6

Internet

http://link.springer.com/article/10.1186/s13045-018-0604-6

Similar Items